Tazemetostat | EZH2 inhibitor
NMR (Conforms)
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 5 mg | $55.00 | ||
| 25 mg | $175.00 |
Tazemetostat (1403254-99-8) is a potent (Ki = 2.5nM wild type human PRC2-containing) and selective SAM-competitive inhibitor of the lysine methyltransferase EZH2.1 Tazemetostat displayed strong antiproliferative effects against SMARCB1-deleted malignant rhabdoid tumor (MRT) cell lines in vitro. This antitumor activity was also observed in SMARTCB1 mutant mouse xenografts. It displayed potent antitumor activity in various cancer models including non-Hodgkins lymphoma2, pediatric glioma3, small-cell carcinoma of the ovary4, and synovial sarcomas5. Tazemetostat has also been shown to control inflammatory genes by modulating IRF1, IRF8, and STAT1 levels suggesting therapeutic potential for the treatment of neuroinflammatory diseases associated with microglial activation.6
References/Citations:
1) Knutson et al. (2013), Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2; Proc. Natl. Acad. Sci. USA 110 7922
2) Knutson et al. (2014), Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma; Mol.Cancer Ther. 13 842
3) Mohammad et al. (2017), EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas; Nat. Med. 23 483
4) Chan-Penebre et al. (2017), Selective killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models; Mol. Cancer Ther. 16 850
5) Kawano et al. (2016), Preclinical Evidence of Anti-Tumor Activity by EZH2 Inhibition in Human Models of Synovial Sarcoma; PLoS One 11 e0158888
6) Arifuzzaman et al. (2017), Selective inhibition of EZH2 by a small molecule inhibitor regulates microglial gene expression essential for inflammation; Biochem. Pharmacol. 137 61
NMR (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Tazemetostat (1403254-99-8) is a potent (Ki = 2.5nM wild type human PRC2-containing) and selective SAM-competitive inhibitor of the lysine methyltransferase EZH2.1 Tazemetostat displayed strong antiproliferative effects against SMARCB1-deleted malignant rhabdoid tumor (MRT) cell lines in vitro. This antitumor activity was also observed in SMARTCB1 mutant mouse xenografts. It displayed potent antitumor activity in various cancer models including non-Hodgkins lymphoma2, pediatric glioma3, small-cell carcinoma of the ovary4, and synovial sarcomas5. Tazemetostat has also been shown to control inflammatory genes by modulating IRF1, IRF8, and STAT1 levels suggesting therapeutic potential for the treatment of neuroinflammatory diseases associated with microglial activation.6
References/Citations:
1) Knutson et al. (2013), Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2; Proc. Natl. Acad. Sci. USA 110 7922
2) Knutson et al. (2014), Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma; Mol.Cancer Ther. 13 842
3) Mohammad et al. (2017), EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas; Nat. Med. 23 483
4) Chan-Penebre et al. (2017), Selective killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models; Mol. Cancer Ther. 16 850
5) Kawano et al. (2016), Preclinical Evidence of Anti-Tumor Activity by EZH2 Inhibition in Human Models of Synovial Sarcoma; PLoS One 11 e0158888
6) Arifuzzaman et al. (2017), Selective inhibition of EZH2 by a small molecule inhibitor regulates microglial gene expression essential for inflammation; Biochem. Pharmacol. 137 61
Related products
-
Elafibranor | PPARalpha/delta agonist
From $65.00CAS:923978-27-2Catalog Number:10-3901Activity:PPARalpha/delta agonistChemical Name:2-[2,6-Dimethyl-4-[(E)-3-(4-methylsulfanylphenyl)-3-oxoprop-1-enyl]phenoxy]-2-methylpropanoic acidAlternate Name:GFT505Molecular Weight:384.49Molecular Formula:C22H24O4SSolubility:Soluble in DMSO (up to at least 25 mg/ml).Physical Properties:Pale yellow solidPurity:98% by HPLC
NMR (Conforms)Storage Temperature:-20°Stability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month.Shipping Code:RT -
Rucaparib phosphate | PARP1 inhibitor
From $70.00CAS:459868-92-9Catalog Number:10-3321Activity:PARP1 inhibitorChemical Name:8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-oneAlternate Name:AG-14699; PF01367338Molecular Weight:421.36Molecular Formula:C19H18FN3O • H3PO4Solubility:Soluble in DMSO (up to 25 mg/ml).Physical Properties:Yellow solidPurity:98% by HPLC
NMR (Conforms)Storage Temperature:-20°Stability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.Shipping Code:RT -
TCEP HCl | Reducing agent
From $35.00CAS:51805-45-9Catalog Number:10-2961Activity:Reducing agentChemical Name:Tris(-Carboxyethyl)phosphine HClMolecular Weight:286.65Molecular Formula:C9H15O6P • HClSolubility:Soluble in Water (up to 50 mg/ml)Physical Properties:White solidPurity:99% by TLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 1 year from date of purchase as supplied. Solutions in distilled water may be stored at -20°C for up to 1 month.Shipping Code:RT
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
20% OFF
For Postdoc
Customers!
Focus Biomolecules • Plymouth Meeting, PA USA • 1-855-FOCUS21
Focus Biomolecules
Plymouth Meeting, PA USA
1-855-FOCUS21
Website Created by Advanta Advertising LLC.